terça-feira, 6 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 29, 2025

Top trending global stocks of 2025

View original at uk.finance.yahoo.com
Top trending global stocks of 2025 This year has seen some big swings in markets, with both sharp falls and record highs, driven by a number of key stories…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • BT reconfirmed full-year guidance with expected adjusted group revenue at approximately £20bn and EBITDA in the range of £8.2bn to £8.3bn

    80% confidence
  • Tesla will have to recover significant ground lost to Alphabet's Waymo which is already operating hundreds of thousands of rides every week

    80% confidence
  • Equities, bonds and commodities all provided positive returns in 2025, and hopes for interest rate cuts, cooling inflation and steady economic growth give grounds for optimism in 2026

    80% confidence
  • The combination of Liberation Day's tariffs, wars in the Middle East and Eastern Europe, worries over AI impact on jobs, government debts and stock market bubble debates does not look favourable for investors, but many will look back upon 2025 with contentment

    80% confidence
  • Having rebounded from deeply depressed valuations, UK banking sector is now benefiting from strong balance sheets, dependable income, and interest rates that remain in a supportive sweet spot

    80% confidence
  • Tesco raised group adjusted operating profit guidance to between £2.9bn and £3.1bn from previously expected £2.7bn to £3bn

    80% confidence
  • Lloyds led UK-listed banks in 2025 with the share price rally down to solid business progress, interest rates staying higher for longer, and profit progression

    80% confidence
  • There is a price to pay for Lloyds' success - shares are now their most expensive since early 2021 on a price-to-earnings basis and at a 10-year high on a price-to-book basis

    80% confidence
  • The test will be whether Musk can deliver on promises sooner rather than later

    80% confidence
  • Investors have put their faith in Elon Musk to the point they're prepared to make him even richer if he can deliver all that he's promised

    80% confidence
  • Ructions in cryptocurrency and ongoing surges in gold and silver may be harbingers of heightened volatility in 2026

    80% confidence
  • Tesco has strengthened its relative pricing position and improved its brand perception

    80% confidence
  • Tesla has never just been a car maker; its value has always been linked to potential technological advances

    80% confidence
  • Perhaps Lloyds won't be in 2026's list of top FTSE 100 performers unless it does something very special

    80% confidence
  • Tesla has struggled to shake off its CEO's politics and huge issues with competition from Chinese manufacturers

    80% confidence
  • UK banks have been one of the quiet success stories of 2025, outperforming US markets and even the high-flying tech sector

    80% confidence
  • Tesla Robotaxi testing is underway with no occupants in the car

    80% confidence
  • Deutsche Bank remains positive on UK food retail sector into 2026 and sees scope for further earnings momentum at Tesco backed by strong execution and market share growth

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Top trending global stocks of 2025 — Source | Via News | pt.VIA.NEWS